TY - JOUR
T1 - Induced pluripotent stem cells
T2 - Advances to applications
AU - Nelson, Timothy J.
AU - Martinez-Fernandez, Almudena
AU - Yamada, Satsuki
AU - Ikeda, Yasuhiro
AU - Perez-Terzic, Carmen
AU - Terzic, Andre
PY - 2010
Y1 - 2010
N2 - Induced pluripotent stem cell (iPS) technology has enriched the armamentarium of regenerative medicine by introducing autologous pluripotent progenitor pools bioengineered from ordinary somatic tissue. Through nuclear reprogramming, patient-specific iPS cells have been derived and validated. Optimizing iPS-based methodology will ensure robust applications across discovery science, offering opportunities for the development of personalized diagnostics and targeted therapeutics. Here, we highlight the process of nuclear reprogramming of somatic tissues that, when forced to ectopically express stemness factors, are converted into bona fide pluripotent stem cells. Bioengineered stem cells acquire the genuine ability to generate replacement tissues for a wide-spectrum of diseased conditions, and have so far demonstrated therapeutic benefit upon transplantation in model systems of sickle cell anemia, Parkinson's disease, hemophilia A, and ischemic heart disease. The field of regenerative medicine is therefore primed to adopt and incorporate iPS cell-based advancements as a next generation stem cell platforms.
AB - Induced pluripotent stem cell (iPS) technology has enriched the armamentarium of regenerative medicine by introducing autologous pluripotent progenitor pools bioengineered from ordinary somatic tissue. Through nuclear reprogramming, patient-specific iPS cells have been derived and validated. Optimizing iPS-based methodology will ensure robust applications across discovery science, offering opportunities for the development of personalized diagnostics and targeted therapeutics. Here, we highlight the process of nuclear reprogramming of somatic tissues that, when forced to ectopically express stemness factors, are converted into bona fide pluripotent stem cells. Bioengineered stem cells acquire the genuine ability to generate replacement tissues for a wide-spectrum of diseased conditions, and have so far demonstrated therapeutic benefit upon transplantation in model systems of sickle cell anemia, Parkinson's disease, hemophilia A, and ischemic heart disease. The field of regenerative medicine is therefore primed to adopt and incorporate iPS cell-based advancements as a next generation stem cell platforms.
KW - Individualized medicine
KW - Regenerative medicine
KW - Stem cell therapy
KW - iPS
UR - http://www.scopus.com/inward/record.url?scp=77958570863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958570863&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:77958570863
SN - 1178-6957
VL - 3
SP - 29
EP - 37
JO - Stem Cells and Cloning: Advances and Applications
JF - Stem Cells and Cloning: Advances and Applications
IS - 1
ER -